T cell adoptive immunotherapy of newly diagnosed gliomas.

摘要: Patients with newly diagnosed gliomas were treated with adoptive transfer of ex vivo activated T lymphocytes, derived from lymph nodes (LNs) draining autologous tumor vaccines, to determine the long-term toxicity of this treatment. Twelve consecutive patients were enrolled: 2 grade II astrocytoma, 4 anaplastic gliomas, and 6 with glioblastoma multiforme. Patients injected intradermally with short-term cultured irradiated cells, admixed with granulocyte macrophage colony-stimulating factor, stimulate draining LNs. The LN cells staphylococcal enterotoxin A for 48 h then in medium containing interleukin an additional 6–8 days subsequently transferred i.v. the patients. number obtained LNs ranged from 9 × 10 7 1.1 , the median cell proliferation was 41-fold. dose infused ranged 0.6 5.5 a median of 1.1 majority which CD 4 + (mean, 71%). entire treatment performed as outpatient therapy associated or less, consisting mainly fever, nausea, myalgias during first 24 h. There no indications late adverse events this treatment even among three follow-up greater than years post transfer. Moreover, four demonstrated partial regression residual tumor. This Phase I clinical trial adoptive immunotherapy malignant gliomas demonstrates feasibility, lack long-term toxicity, several objective responses.